Clinicians should strongly consider prescribing or co-prescribing naloxone to certain patients at risk for opioid overdose, and educating them about its use, according to guidance released today by the Department of Health and Human Services. For example, the recommendation includes patients prescribed opioids who are receiving them at a dosage of 50 morphine milligram equivalents per day or greater; have respiratory conditions such as chronic obstructive pulmonary disease or obstructive sleep apnea; have been prescribed benzodiazepines; or have a substance use disorder, excessive alcohol use or mental health disorder. “This new guidance reflects our commitment to ensuring those who need overdose-reversing drugs have them and provides practical steps that clinicians, patients, and the public can take to reduce the risk of an overdose,” said HHS Secretary Alex Azar.

Related News Articles

Headline
Under a new Centers for Medicare…
Headline
Six health care organizations in rural North Carolina communities will share $1.2 million in federal grant funds to strengthen and expand their response to…
Headline
The Food and Drug Administration yesterday released new draft guidance for labeling medications that carry the risk of abuse or dependence, including but not…
Headline
The National Academy of Medicine Action Collaborative on Countering the U.S. Opioid Epidemic will host a free public webinar July 22 at 3 p.m. ET on best…
Headline
The Centers for Medicare…
Headline
The House Ways and Means Committee today passed the Opioid Workforce Act (H.R. 3414), AHA-supported legislation that would add 1,000 Medicare-funded training…